Maternal-fetal interactions, predictive markers for preeclampsia, and programming

Journal of Reproductive Immunology

Volumn 108, Issue , 2015, Pages 26-32

  Huppertz, Berthold ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

Biomarker; Prediction; Preeclampsia; Pregnancy; Programming

Indexed keywords

BIOLOGICAL MARKER; ENDOGLIN; HEMOGLOBIN F; PLACENTA PROTEIN; PLACENTA PROTEIN 13; PLACENTAL GROWTH FACTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; GALECTIN; LGALS13 PROTEIN, HUMAN; MEMBRANE PROTEIN; PIGF PROTEIN, HUMAN;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CARDIOVASCULAR SYSTEM; FETUS GROWTH; HUMAN; LONG TERM CARE; MATERNAL BLOOD; MORBIDITY; MOTHER FETUS RELATIONSHIP; PLACENTA; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; SCAVENGING SYSTEM; SYNCYTIOTROPHOBLAST; ANIMAL; CHILD; FEMALE; FETOMATERNAL TRANSFUSION; IMMUNOLOGY; METABOLISM; PASSIVE IMMUNIZATION; PRE-ECLAMPSIA; PREGNANCY; PROGNOSIS;

ANIMALS; BIOMARKERS; CHILD; CHILD OF IMPAIRED PARENTS; FEMALE; GALECTINS; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; MATERNAL-FETAL EXCHANGE; MEMBRANE PROTEINS; PLACENTA; PRE-ECLAMPSIA; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY PROTEINS; PROGNOSIS;

EID: 84926251635     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2014.11.003     Document Type: Article

References (47)

1. ACOG practice bulletin Diagnosis and management of preeclampsia and eclampsia. Number 33, 2002. American College of Obstetricians and Gynecologists. ACOG Committee on Obstetric Practice. Int. J. Gynaecol. Obstet. 2002, 77:67-75.
2. Aird W.C. Spatial and temporal dynamics of the endothelium. J. Thromb. Haemost. 2005, 3:1392-1406.
3. Akolekar R., Zaragoza E., Poon L.C., Pepes S., Nicolaides K.H. Maternal serum placental growth factor at 11+0 to 13+6 weeks of gestation in the prediction of pre-eclampsia. Ultrasound Obstet. Gynecol. 2008, 32:732-739.
4. Anderson U.D., Olsson M.G., Rutardóttir S., Centlow M., Kristensen K.H., Isberg P.E., Thilaganathan B., Akerström B., Hansson S.R. Fetal hemoglobin and α1-microglobulin as first- and early second-trimester predictive biomarkers for preeclampsia. Am. J. Obstet. Gynecol. 2011, 204:520.e1-520.e5.
5. Benirschke K., Kaufmann P., Baergen R.N. Pathology of the Human Placenta 2006, 42-49. Springer, New York.
6. Burton G.J., Watson A.L., Hempstock J., Skepper J.N., Jauniaux E. Uterine glands provide histiotrophic nutrition for the human fetus during the first trimester of pregnancy. J. Clin. Endocrinol. Metab. 2002, 87:2954-2959.
7. Burton G.J., Woods A.W., Jauniaux E., Kingdom J.C. Rheological and physiological consequences of conversion of the maternal spiral arteries for uteroplacental blood flow during human pregnancy. Placenta 2009, 30:473-482.
8. Cetin I., Huppertz B., Burton G., Cuckle H., Gonen R., Lapaire O., Mandia L., Nicolaides K., Redman C., Soothill P., Spencer K., Thilaganathan B., Williams D., Meiri H. Pregenesys pre-eclampsia markers consensus meeting: what do we require from markers, risk assessment and model systems to tailor preventive strategies?. Placenta 2011, 32(Suppl.):S4-S16.
9. Chafetz I., Kuhnreich I., Sammar M., Tal Y., Gibor Y., Meiri H., Cuckle H., Wolf M. First-trimester placental protein 13 screening for preeclampsia and intrauterine growth restriction. Am. J. Obstet. Gynecol. 2007, 197:35.e1-35.e7.
10. Cheng S.J., Lee J.J., Cheng S.L., Chen H.M., Chang H.H., Wang Y.P., Kok S.H., Kuo M.Y., Chiang C.P. Increased serum placenta growth factor level is significantly associated with progression, recurrence and poor prognosis of oral squamous cell carcinoma. Oral Oncol. 2012, 48:424-428.
11. Clark D.E., Smith S.K., Licence D., Evans A.L., Charnock-Jones D.S. Comparison of expression patterns for placenta growth factor, vascular endothelial growth factor (VEGF), VEGF-B and VEGF-C in the human placenta throughout gestation. J. Endocrinol. 1998, 159:459-467.
12. Cowans N.J., Stamatopoulou A., Matwejew E., von Kaisenberg C.S., Spencer K. First-trimester placental growth factor as a marker for hypertensive disorders and SGA. Prenat. Diagn. 2010, 30:565-570.
13. Duley L. The global impact of preeclampsia and eclampsia. Semin. Perinatol. 2009, 33:130-137.
14. Gizurarson S., Huppertz B., Osol G., Skarphedinsson J.O., Mandala M., Meiri H. Effects of placental protein 13 on the cardiovascular system in gravid and non-gravid rodents. Fetal Diagn. Ther. 2013, 33:257-264.
15. Goswami D., Tannetta D.S., Magee L.A., Fuchisawa A., Redman C.W., Sargent I.L., von Dadelszen P. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta 2006, 27:56-61.
16. Hansson S.R., Gram M., Akerström B. Fetal hemoglobin in preeclampsia: a new causative factor, a tool for prediction/diagnosis and a potential target for therapy. Curr. Opin. Obstet. Gynecol. 2013, 25:448-455.
17. Hogg K., Blair J.D., McFadden D.E., von Dadelszen P., Robinson W.P. Early onset pre-eclampsia is associated with altered DNA methylation of cortisol-signalling and steroidogenic genes in the placenta. PLOS ONE 2013, 8:e62969.
18. Huppertz B. Placental origins of preeclampsia: challenging the current hypothesis. Hypertension 2008, 51:970-975.
19. Huppertz B. Biology of the placental syncytiotrophoblast - myths and facts. Placenta 2010, 31(Suppl.):S75-S81.
20. Huppertz B. Placental pathology in pregnancy complications. Thromb. Res. 2011, 127(Suppl. 3):S96-S99.
21. Huppertz B., Kadyrov M., Kingdom J.C. Apoptosis and its role in the trophoblast. Am. J. Obstet. Gynecol. 2006, 195:29-39.
22. Huppertz B., Sammar M., Chefetz I., Neumaier-Wagner P., Bartz C., Meiri H. Longitudinal determination of serum placental protein 13 during development of preeclampsia. Fetal Diagn. Ther. 2008, 24:230-236.
23. Huppertz B., Meiri H., Gizurarson S., Osol G., Sammar M. Placental protein 13 (PP13): a new biological target shifting individualized risk assessment to personalized drug design combating pre-eclampsia. Hum. Reprod. Update 2013, 19:391-405.
24. Johansen M., Redman C.W., Wilkins T., Sargent I.L. Trophoblast deportation in human pregnancy - its relevance for pre-eclampsia. Placenta 1999, 20:531-539.
25. Kaufmann P., Huppertz B., Frank H.G. The fibrinoids of the human placenta: origin, composition and functional relevance. Ann. Anat. 1996, 178:485-501.
26. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., Schisterman E.F., Thadhani R., Sachs B.P., Epstein F.H., Sibai B.M., Sukhatme V.P., Karumanchi S.A. Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 2004, 350:672-683.
27. Longtine M.S., Nelson D.M. Placental dysfunction and fetal programming: the importance of placental size, shape, histopathology, and molecular composition. Semin. Reprod. Med. 2011, 29:187-196.
28. Meler E., Scazzocchio E., Peguero A., Triunfo S., Gratacos E., Figueras F. Role of maternal plasma levels of placental growth factor for the prediction of maternal complications in preeclampsia according to the gestational age at onset. Prenat. Diagn. 2014, 34:706-710.
29. Moser G., Gauster M., Orendi K., Glasner A., Theuerkauf R., Huppertz B. Endoglandular trophoblast, an alternative route of trophoblast invasion? Analysis with novel confrontation co-culture models. Hum. Reprod. 2010, 25:1127-1136.
30. Moser G., Orendi K., Gauster M., Siwetz M., Helige C., Huppertz B. The art of identification of extravillous trophoblast. Placenta 2011, 32:197-199.
31. Nicolaides K.H., Bindra R., Turan O.M., Chefetz I., Sammar M., Meiri H., Tal J., Cuckle H.S. A novel approach to first-trimester screening for early pre-eclampsia combining serum PP-13 and Doppler ultrasound. Ultrasound Obstet. Gynecol. 2006, 27:13-17.
32. Ohkuchi A., Hirashima C., Matsubara S., Suzuki H., Takahashi K., Arai F., Watanabe T., Kario K., Suzuki M. Alterations in placental growth factor levels before and after the onset of preeclampsia are more pronounced in women with early onset severe preeclampsia. Hypertens. Res. 2007, 30:151-159.
33. Olsson M.G., Centlow M., Rutardóttir S., Stenfors I., Larsson J., Hosseini-Maaf B., Olsson M.L., Hansson S.R., Akerström B. Increased levels of cell-free hemoglobin, oxidation markers, and the antioxidative heme scavenger alpha(1)-microglobulin in preeclampsia. Free Radic. Biol. Med. 2010, 48:284-291.
34. Pan P., Fu H., Zhang L., Huang H., Luo F., Wu W., Guo Y., Liu X. Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol. 2010, 11:36.
35. Pilalis A., Souka A.P., Antsaklis P., Basayiannis K., Benardis P., Haidopoulos D., Papantoniou N., Mesogitis S., Antsaklis A. Screening for pre-eclampsia and small for gestational age fetuses at the 11-14 weeks scan by uterine artery Dopplers. Acta Obstet. Gynecol. Scand. 2007, 86:530-534.
36. Redman C.W.G., Sargent I.L. Placental debris, oxidative stress and pre-eclampsia. Placenta 2000, 21:597-602.
37. Robinson C.J., Johnson D.D., Chang E.Y., Armstrong D.M., Wang W. Evaluation of placenta growth factor and soluble Fms-like tyrosine kinase 1 receptor levels in mild and severe preeclampsia. Am. J. Obstet. Gynecol. 2006, 195:255-259.
38. Rochette J., Craig J.E., Thein S.L. Fetal hemoglobin levels in adults. Blood Rev. 1994, 8:213-224.
39. Sammar M., Nisamblatt S., Gonen R., Huppertz B., Gizurarson S., Osol G., Meiri H. The role of the carbohydrate recognition domain of placental protein 13 (PP13) in pregnancy evaluated with recombinant PP13 and the DelT221 PP13 variant. PLOS ONE 2014, 9:e102832.
40. Schaarschmidt W., Rana S., Stepan H. The course of angiogenic factors in early- vs. late-onset preeclampsia and HELLP syndrome. J. Perinat. Med. 2013, 41:511-516.
41. Smith G.C., Crossley J.A., Aitken D.A., Jenkins N., Lyall F., Cameron A.D., Connor J.M., Dobbie R. Circulating angiogenic factors in early pregnancy and the risk of preeclampsia, intrauterine growth restriction, spontaneous preterm birth, and stillbirth. Obstet. Gynecol. 2007, 109:1316-1324.
42. Staff A.C., Benton S.J., von Dadelszen P., Roberts J.M., Taylor R.N., Powers R.W., Charnock-Jones D.S., Redman C.W. Redefining preeclampsia using placenta-derived biomarkers. Hypertension 2013, 61:932-942.
43. Stepan H., Krämer T., Faber R. Maternal plasma concentrations of soluble endoglin in pregnancies with intrauterine growth restriction. J. Clin. Endocrinol. Metab. 2007, 92:2831-2834.
44. Su A.I., Wiltshire T., Batalov S., Lapp H., Ching K.A., Block D., Zhang J., Soden R., Hayakawa M., Kreiman G., Cooke M.P., Walker J.R., Hogenesch J.B. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:6062-6067.
45. Sverrisson K., Axelsson J., Rippe A., Gram M., Åkerström B., Hansson S.R., Rippe B. Extracellular fetal hemoglobin induces increases in glomerular permeability: inhibition with α1-microglobulin and tempol. Am. J. Physiol. Renal. Physiol. 2014, 306:F442-F448.
46. Williams D. Long-term complications of preeclampsia. Semin. Nephrol. 2011, 31:111-122.
47. World Health Organization Make Every Mother and Child Count. World Health Report 2005, World Health Organization, Geneva, Switzerland.